Lilly just lowered the price of Zepbound.One of the biggest growth narratives in the pharmaceutical industry right now is about weight loss medications. Glucagon-like peptide-1 (GLP-1) agonists such as Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are becoming ever more popular among diabetes and obesity care patients.All of these medications are made by just two companies: Novo Nordisk and Eli Lilly (LLY -1.07%). For now, Novo Nordisk is the 800-pound gorilla in the GLP-1 arena. But Lilly has made sign ...